The abstract is read at the publisher; the summary is JClub's.
The CHARGE prognostic index stratifies relapsed/refractory multiple myeloma patients receiving BCMA- or talquetamab T-cell engagers into three PFS risk groups, including a high-risk median PFS of 1.6 months.
- Why it matters: Outcomes after bispecific T-cell engagers in RRMM vary widely, and clinicians need a practical way to predict progression-free survival for patients starting BCMA- or GPRC5D-directed therapy.
- What they did: Using multivariable Cox modeling, the study combined six factors—HRCAs, hyperferritinemia, anemia, early relapse, ECOG performance status ≥2, and prior BCMA-directed exposure—to build CHARGE, then validated it in an independent multicenter International Myeloma Foundation cohort.
- The result: In 577 BCMA-directed and 366 talquetamab treatments (median follow-up 8.4 months), median PFS was 21.8, 7.1, and 1.6 months across low-, intermediate-, and high-risk groups; external validation (n=173) gave not reached, 7.0, and 3.0 months.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.